Journal of Microbiology and Biotechnology

The Korean Society for Microbiology and Biotechnology (한국미생물·생명공학회)
권호 표지

Improvement of Virus Safety of a Human Intravenous Immunoglobulin by Low pH Incubation

  • Kim, In-Seop (Technical Operations Service, Central Research Center, Green Cross Plasma Derivatives Co.) ;
  • Choi, Yong-Woon (Technical Operations Service, Central Research Center, Green Cross Plasma Derivatives Co.) ;
  • Lee, Sung-Rae (Technical Operations Service, Central Research Center, Green Cross Plasma Derivatives Co.) ;
  • Cho, Hang-Bok (Technical Operations Service, Central Research Center, Green Cross Plasma Derivatives Co.) ;
  • Eo, Ho-Gueon (Technical Operations Service, Central Research Center, Green Cross Plasma Derivatives Co.) ;
  • Han, Sang-Woo (Technical Operations Service, Central Research Center, Green Cross Plasma Derivatives Co.) ;
  • Chang, Chong-Eun (Technical Operations Service, Central Research Center, Green Cross Plasma Derivatives Co.) ;
  • Lee, Soung-Min (Technical Operations Service, Central Research Center, Green Cross Plasma Derivatives Co.)
  • Published : 2001.08.01
Download PDF
⟨ Previous Next ⟩

Abstract

n order to increase the virus safety of a human intravenous immunoglobulin (IVIg) that was manufactured by a successive process of cold ethanol fractionation, polyethylene glycol precipitation, and pasteurization ($60^{\circ}C$ heat treatment for 10h), a low pH incubation process (pH 3.9 at $25{\circ}C$ for 14 days) was employed as the final step. The efficacy and mechanism of the fraction III cold ethanol fractionation, pasteurization, and low pH treatment steps in the removal and/or inactivation of blood-borne viruses were closely examined. A variety of experimental model viruses for human pathogenic viruses, including the Bovine herpes virus (BHV), Bovine viral diarrhoea virus (BVDV), Murine encephalomyocarditis virus (EMCV), and Porcine parvovirus (PPV), were selected for this study. The mechanism of reduction for the enveloped viruses (BHV and BVDV) during fraction III fractionation was both inactivation and partitioning, however, it was partitioning in the case of the nonenveloped viruses (EMCV and PPV). The log reduction factors achieved during fraction III fractionation were ${\geqq}$6.7 for BHV, ${\geqq}4.7$ for BVDV, 4.5 for EMCV, and 4.4 for PPV. Pasteurization was found to be a robust and effective step in inactivating all the viruses tested. The log reduction factors achieved during the pasteurization process were ${\geqq}7.5$ for BHV, ${\geqq}4.8$ for BVDV, 3.0 for EMCV, and 3.3 for PPV. A low pH incubation was very effective in inactivating the enveloped viruses as well as EMCV. The log reduction factors achieved during low pH incubation were ${\geqq}7.4$ for BHV, ${\geqq}3.9$ for BVDV, 5.2 for EMCV, and 2.0 for PPV. These results indicate that the low pH treatment successfully improved the viral safety of the final products.

Keywords

References

  1. Biologicals v.26 Inactivation kinetics of model and relevant bloodborne viruses by treatment with sodium hydroxide and heat Borovec, S.;C.Broumis;W. Adcock;R. Fang;E. Uren
  2. Biologicals v.26 Virus validation of pH 4-treated human immunoglobulin products produced by the Cohn fractionaltion process Bos O.J.M.;D. G. J. Sunye;C. E. F. Nieuweboer;F.A.C. van Engelenburg;H. Schuitemaker;J. Over
  3. J. Am. Chem. v.68 Preparation and properties of serum and plasma proteins. ,Ⅳ. A system for the scparation into fractions of the proteins and lipoprotein components of biological tissues and fluids Cohn, E.J.;L.E. strong;W.L.Jr. Hughes;D.J. Mulford;J.N. Ashworth;M. Melin;H.L. Taylor
  4. J. Infect. v.15 The viral safety of intravenous immunoglobulin Cuthbertson, B.;R. J. Perry;P.R. Foster;K.G. Reid;R.J. Crawford;P.L. Yap
  5. Biologicals v.24 Improvement of virus safety of a S/D-treated factor Ⅷ concentrate by additional dry heat treatment at 100℃ Dichtelmuller, H.;D. rudnick;B. Breuer;R. Kotitschke;M. Kloft;A. Darling;E. Watson;B. Flehmig;S. Lawson;G. Frosner
  6. Clin. Exp. Rheumatol. v.Suppl15 Immunoglobulins in autoimmunity: History and mechanism of action Dwyer, J.M.
  7. pharmacotherapy v.7(Suppl) Methodology and safety sonsiderations in the production of an intravenous immunoglobulin preparation Friedli, H.R.
  8. Vox Sang v.63 Virus inactivation during intravenous immunoglobulin production Hamalainen, E.;H. suomela;R. Ukkonen
  9. J. Microbiol. Biotechnol v.8 Expression and characterization of recombinant E2 protein of hepatitis C virus by insect Cell/baculovirus expression system Han, B.W.;N. Lee;M. K. Min;K. H. Jung
  10. Curr. Stud. Hematol. Blood Transfus v.56 Strategies to produce virus-safe blood derivatives Heimburger, N.;H. E. Karges
  11. Transfusion v.25 Evaluation of two viral inactivation methods for the preparation of safer factor Ⅷ and factor Ⅸ concentrates Heldebrant, C.M.;E. D. Gomperts;C. K. Kasper;J. S. McDougal;A. E. Friedman;D. S. Hwang;E. Muchmore;S. Jordan;R. Miller;E. Sergis-Da-venport;W. Lam
  12. Federal Resister v.63(185) Guidance on viral safety evaluation of biotechnology products derived from cell lines of human or animal origin:Availability International Conference on Harmonisation
  13. Arch. Exp. Path. Pharmak v.162 Beitrag zur kollectiven Behandlung pharmakologische Reihenversuche Karber, J.
  14. Transfusion v.31 virus inactivation during production of intravenous immunoglobulin Kemph, C.;P. Jentsch;B. Poirier;F. Barre-Sinoussi;J.J. Morgenthaler;A. Morell;D. Germann
  15. J. Microbiol. Biotechnol. v.9 large-scale culture of hepatitis a virus in human diploid MRC-5 cells and partial purification of the viral antigen for use as a vaccine Kim, H.-S.;Y.-J. Chung;Y.-J. Jeon;S.-H. Lee
  16. J. Microbiol. Biotechnol v.10 partitioning and inactivation of viruses by cold ethanol fractionation and pasteurization during manufacture of albumin from human plasma Kim, I. S.;H. G. Eo;C.E. Chang;S. Lee
  17. J.Micropiol v.38 Solvent/detergent inactivation and chromatographic removal of human immunodeficiency virus during the manufacturing of a high purity antihemophilic factor Kim, I.S.;Y.W. Choi;H. S. Woo;C. E. Chang;S. Lee
  18. Lancet v.2 Non-A, non-B hepatitis from intravenous immunoglobulin Lane, R.S.
  19. Virology (3rd ed.) Levy, J. A.;H. Fraenkel-Conrat;R.A. Owens
  20. Biologicals v.22 Inactivation of hepatitis C virus in low pH intravenous immunoglobulin Louie, R.E.;C.J. Galloway;M.L. Dumas;M.F. Wong;G. Mitra
  21. Prog. Clin. Biol.Res. v.182 Measures to inactivate viral contaminants of pooled plasma products Menache, D.;D. L. Aronson
  22. Beitr infusionsther v.24 Inactivation of viruses and safety of stable plasma products Morgenthaler, J.J.
  23. J. Med. Virol. v.36 Virus safety of human immunoglobulins:Efficient inactivation of hepatitis C and other human pathogenic viruses by the manufacturing procedure Nowak, T.;J.-P. Gregersen;U. Kockmann;L. B. Cummins;J. Hilfenhaus
  24. Dev. Bio. Stand. v.81 Inactivation of HIV, HBV, DCV related viruses and other viruses in human plasma derivatives by pasteurization Nowak, T.;M. Niedrig;D. Bernhardt;J. Hilfenhaus
  25. Lancet v.1 Non-A non-B hepatitis and intravenous immunoglobulin Ochs, H. D.;S.H. Fischer;F.S. Virant;M. L. Lee;H.S. Kingdon;R.J. Wedgwood
  26. Transfusion v.36 Virus inactivation by pepsin treatment at pH 4 of IgG solutions: Factors affecting the rate of virus inactivation Omar, A.;C. Kempf;A. Immelmann;M. Rentsch;J.-J. Morgenthaler
  27. J. Am. Chem. v.71 The separation of the antibodies, isoagglutinins, prothrombin, plasminogen and β₁-lipoprotein into subfractions of human plasma Oncley, J.L.;M. Nelin;D.A. Richert;J.W. Cameron;P.M.Jr. Gross
  28. J. Microbiol. Biotechnol. v.9 purification and characterizaiton of recombinant hepatitis C virus replicase Park, C.;Y. Kee;J. Lee;J. Oh,;J. Park;H. Myung
  29. Vox Sang v.72 Human parvovirus B19 and blood products Prowse, C.;C. A. Ludlam;P. I. Yap
  30. Biologicals v.25 Measurement of anticomplementary activity in therapeutic intravenous immunoglobulin preparatin Ramasamy, I.;E. Tran;A. Farrugia
  31. Pediatr. Rev. v.16 Therapeutic uses of intravenous immunoglobilin(IVIg) in children Ramesh, S.;S. A. schwartz
  32. Vox Sang v.55 Potential contribution of mild pepsin treatment at pH4 to the viral safety o human immunoglobulin products Reid, K. G.;B. Cuthbertson;S. D. L. Jones;R.V. McIntosh
  33. Transfusion v.37 Transmission of parvovirus B19 by coagulation factor concentrates exposed to 100℃ heat after lyophilization Santagostino, E.;P.M. Mannucci;A. Gringeri;A. Azzi;M. Morfini;R. Santoro;M. Schiavoni
  34. Intervirology v.23 Characteristics and taxonomy of Parvoviridae Siegl, G.;R.C. Bates;K.I. Berns;B.J. Carter;D.C. Kelly;E. Kurstak;P. Tattersall
  35. Pediatr. Infect. Dis. v.16 Human intravenous immunoglobulin in primary and secondary antibody deficiencies Stiehm, E.R.
  36. Transfusion v.35 hepatitis C virus infection in hypogammaglobulinemic patients receiving long-term replacement therapy with intravenous immunoglobulin Taliani,G.;E. Guerra;R. Lecce;C. De Bac;F. aiuti
  37. Vox Sang v.67 Inactivation and elimination fo viruses during preparation of human intravenous immunoglobulin Uemura, Y.;Y.H.J. Yang;C.M. Heldebrant;J. Takechi;K. Yokoyama
  38. Lancet v.1 Non-A, non-B hepatitis after intravenous gammaglobulin Weiland, O.;L. Mattson;H. Glaumann
  39. Clin. Exp. Immunol. v.104(Suppl 1) The viral safety of intravenous immune globulin Yap, P. L.
  40. Clin. Exp. Immunol. v.104 no.SUP. 1 The viral safety of intravenous immuneglobulin Yap,P.L.